Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000702860 | SCV000831732 | likely benign | Neurofibromatosis, type 1 | 2024-05-22 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002319093 | SCV001176880 | uncertain significance | Hereditary cancer-predisposing syndrome; Cardiovascular phenotype | 2023-06-29 | criteria provided, single submitter | clinical testing | The p.I86V variant (also known as c.256A>G), located in coding exon 3 of the NF1 gene, results from an A to G substitution at nucleotide position 256. The isoleucine at codon 86 is replaced by valine, an amino acid with highly similar properties. This amino acid position is highly conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Genome- |
RCV000702860 | SCV002561429 | uncertain significance | Neurofibromatosis, type 1 | 2022-03-15 | criteria provided, single submitter | clinical testing | |
New York Genome Center | RCV000702860 | SCV004176195 | uncertain significance | Neurofibromatosis, type 1 | 2023-07-24 | criteria provided, single submitter | clinical testing |